Paraoxonase Activity, But Not Haplotype Utilizing the Linkage Disequilibrium Structure, Predicts Vascular Disease W e have previously reported that paraoxonase (PON1) activity for the hydrolysis of paraoxon (POase) or diazoxon (DZOase) predicted carotid artery disease (CAAD) status, even though PON1 Q192R , the Gln(Q) to Arg(R) substitution at amino acid 192, and PON1 L55M , the Leu(L) to Met(M) substitution at amino acid 55, coding region polymorphisms were not marginally predictive of disease. 1 This result has recently been confirmed to be true for coronary heart disease. 2 The inhibition or reduction of atherogenic LDL oxidation by HDL seems, at least in part, to be a function of PON1, which is physically associated with the HDL particle. [3] [4] [5] [6] [7] Thus, the PON1-CVD association is expected to result from the role of PON1 in the metabolism of bioactive lipid molecules and protection against damage caused by oxidized low-density lipoprotein (LDL). PON1 knockout mice are devoid of PON1 hydrolysis activity in plasma and liver 8 and are more susceptible to atherosclerosis. 9 
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Association studies of the PON1 192 or PON1 55 polymorphisms with vascular disease have had mixed results, with only some finding an excess of the PON1 192R or PON1 55L alleles associated with cardiovascular disease. 10 -25 Our previous work suggested that unmeasured factors that alter PON1 hydrolysis activity were important in heart disease. 1 We hypothesized that lowered protein concentration attributable to PON1 5Ј regulatory region polymorphisms might predict both the reduced activity and disease status. We subsequently identified 5 promoter region polymorphisms 26 and used in vitro luciferase expression studies to determine that 2 polymorphisms, PON1 Ϫ108 and PON1 Ϫ162 , influenced PON1 expression levels. 27 The PON1 Ϫ108 polymorphism accounted for 23% of the variance in PON1 expression. 27 Additionally, as detailed below, smoking may depress PON1 activity and statin use may elevate PON1 activity, so PON1 activity effects in vascular disease may also reflect these environmental exposures.
The goal of this study was to further the understanding of the role of PON1 activity in CAAD and determine if a fraction of the reduced activity in cases was attributable to differences in PON1 5Ј region variations or to differences in smoking or statin use. We also considered haplotype effects, which offer the potential advantage of higher heterozygosi-ty 28 and may capture the effects of even unsampled diseasecausing mutations. 29 Gabriel et al 30 identified sizable regions with little recombination and with only a few common haplotypes, sometimes referred to as haplotype blocks. These authors estimated that most of the human genome is contained in large blocks and that within a block, 90% of all chromosomes are captured by only 3 to 5 haplotypes. However, utility of haplotype depends on the LD structure of the gene of interest. Therefore, this was investigated for PON1 in 23 white subjects. The LD structure then determined the strategy for the testing of PON1 polymorphism effects in vascular disease.
In addition to paraoxon and diazoxon, PON1 hydrolyzes phenylacetate and the nerve agents soman and sarin. PON1 arylesterase (Aase) activity in the hydrolysis of phenylacetate was known to be only slightly impacted by the PON1 192 polymorphism 27, 31 and thus more reflective of the concentration of PON1 protein present. Because of our interest in the changes in the amount of protein that are expected by the functional 5Ј region variants, we added Aase as a PON1 activity measure.
Methods

Subjects
The present sample of 302 white men used to evaluate the role of PON1 in vascular disease was expanded from the 212 men previously reported to lack marginal effects of the PON1 coding regions on CAAD prediction. 1 All subjects were collected from Puget Sound Veterans Affairs Health Care System (PSVAHCS). The cases had greater than 80% internal carotid artery stenosis, unilaterally or bilaterally, on angiography or had undergone a carotid endarterectomy. All controls were drawn from patients without codes for vascular disease who subsequently were shown to have had less than 15% internal carotid artery stenosis, bilaterally, on carotid duplex ultrasound. Subjects with total serum cholesterol greater than 400 mg/dL or with known coagulopathies were excluded. Subjects were matched by censored age (within 12 months). Race was ascertained from both PSVAHCS record and self-report. Censored age matching was based on the age at time of blood draw for controls and age at diagnoses of carotid artery disease for cases. The mean duration of documented vascular disease before sampling of cases was 2.6 years. The study was approved by both the University of Washington and the PSVAHCS human subject review processes. Subjects gave written informed consent. These subjects had a mean censored age of 65.8 years (range, 41 to 84 years). Of the 302 white male subjects, 38% were taking lipid-lowering medications (from the patients' pharmacy medication history) and 68% were current smokers or former smokers (dichotomous traits, by self-report).
Twenty-three white individuals (46 chromosomes) from the Center d'Etude du Polymorphisme Humain (CEPH) genomics repository were fully sequenced for the PON1 region. This separate sample was used to generate the linkage disequilibrium data summarized in Figure 1 .
PON1 Genotype and Activity Phenotype Methods
DNA was prepared from buffy coat preparations by a modification of the procedure of Miller et al 32 using Puregene reagents (Gentra). All genotyping was conducted by polymerase chain reaction amplification followed by polymorphism-specific restriction digestion and gel electrophoresis. The PON1 Q192R polymorphism was detected by Alw I digestion and the PON1 L55M polymorphism was detected by Nla III digestion as published previously. 33 The genotype of the PON1 C-108T polymorphism and the PON1 A-162G polymorphism were determined by Bst UI digestion as described 26, 27 Genotype distributions did not significantly differ from Hardy-Weinberg equilibrium expectations.
PON1 paraoxon (POase activity) and diazoxon (DZOase activity) hydrolysis rates were measured spectrophotometrically with lithium heparin plasma, as described. 34 All samples were run in duplicate; the averaged value was used for analysis. PON1 192 genotype can be predicted with high accuracy from examination of the 2D plot of paraoxon and diazoxon hydrolysis rates. 34 When assignments did not match, both genotyping and phenotyping studies were repeated. Three hundred subjects had genotype-phenotype agreement. Two subjects genotyped as PON1 192QR and phenotyped as PON1 192RR , indicating a nonfunctional Q allele. Sequencing of the coding regions confirmed the PON1 192QR genotype but failed to detect a coding region change that would account for the inactive allele. Arylesterase activities were performed in triplicate as described. 27 
Lipid Measurements
Lipid measurements were performed on fasting whole plasma. Standard enzymatic methods were used to determine levels of total cholesterol, triglycerides, and HDL cholesterol on an Abbott Spectrum analyzer. [35] [36] [37] LDL cholesterol was calculated. 38 Apolipoprotein AI measurement methods were as previously reported. 39 
Statistical Methods
Linkage disequilibrium across the 26-kb PON1 region was assessed in the 23 white subjects from the CEPH sample that were fully sequenced for this region by the SeattleSNPs program. These sequences are publicly available at http://pga.mbt.washington.edu. The linkage disequilibrium statistics DЈ and r 2 were both computed for each pair of single nucleotide polymorphisms (SNPs) with an observed minor allele frequency (MAF) of greater than or equal to 10%. Given 2 SNPs (A and B) with 2 alleles each (A1/A2 and B1/B2), the basic metric of LD is D, the difference between the observed number of A1B1 haplotypes and the expected number of A1B1 haplotypes if genotypes were independent at A and B (DϭpA1B1ϪpA1*pB1). The range of D depends on the allele frequencies at A and B, so it is difficult to compare D between marker pairs. DЈ normalizes D to the maximum possible D given the allele frequencies at A and B, so the range of DЈ is (Ϫ1,1) for all pairs of SNPs. |DЈ|ϭ1 if only 3 of the 4 possible haplotypes are observed, so it is a useful statistic for detecting recombination between A and B. r 2 is the Pearson correlation coefficient for alleles at A and B. The range of r 2 depends on how similar allele frequencies are at A and B. If A and B have the same allele frequency, then the range of r 2 is (0,1); otherwise the range is (0,Ͻ1). r 2 ϭ1 if only 2 of the 4 possible haplotypes are observed, meaning that genotype at A and B is perfectly correlated, so r 2 is a useful statistic for determining whether an effect associated with B could be detected by genotyping at A. Haplotypes were inferred for all sites with MAF Ͼ5% using the program PHASE. 40 This allowed us to examine how well haplotypes constructed from the 4 genotyped polymorphisms capture the overall haplotype structure of the gene.
POase (sqrt-POase), DZOase (sqrt-DZOase), and Arylesterase (sqrt-Aase) were square root transformed to reduce positive skewness. Preliminary analyses included the estimation of the variance in sqrt-POase, sqrt-DZOase, and sqrt-Aase attributable to PON1 192 , PON1 55 , PON1 Ϫ108 , or PON1 Ϫ162 genotypes and haplotypes using the r 2 from linear regression. This was done separately for cases and controls. The additional variance in PON1 activity measures explained by current smoking or pack years smoked, statin use, and levels of HDL, HDL2, and HDL3 were sequentially evaluated.
Matched logistic regression was used to test for effects in the prediction of CAAD cases (coded as 1) versus controls (coded as 0). The matched analyses were done using the Cox regression function in SPSS with CAAD status as the outcome, the pair ID as the strata, and a constant survival time of 1 for all subjects and included the covariates to be tested. Separate regressions were tested for a PON1 Ϫ108 or PON1 Ϫ162 genotype effect or a POase or DZOase effect on the prediction of CAAD status. Another logistic regression tested whether the addition of genotype information for all 4 polymorphisms altered the significance of sqrt-POase, sqrt-DZOase, or sqrt-Aase in the prediction of CAAD status. All regression analyses used SPSS 8.0 for Windows. 41 
Results
Patterns of Linkage Disequilibrium Between Common Polymorphic Sites in the PON1 Gene Region
The linkage disequilibrium structure of the PON1 gene region is shown graphically in Figure 1 . The LD statistic DЈ (shown below the diagonal) is useful in detecting historical recombination events.
Where DЈ is useful in detecting recombination, r 2 describes how closely correlated the genotype is between a pair of SNPs, which is critical for association studies. Considering an r 2 above 0.5 as potentially useful for detecting untyped sites, 42 it is clear that typing a single SNP in any given region yields information about some nearby sites, but power to detect untyped sites in other regions of PON1 is dramatically lower. For example, DЈϭ0.775 between PON1 55Leu and PON1 192Arg , suggesting that a modest number of recombinant chromosomes exist. However, the correlation between PON1 55Leu and PON1 192Arg is weak (r 2 ϭ0.087) because the rare allele at each SNP is associated with the common allele at the other SNP, and therefore typing either SNP alone would provide little power to detect risks associated with the other polymorphism.
The observed patterns of DЈ and r 2 suggest that a modest number of sites need to be typed within each nonrecombinant region, consistent with a small number of haplotypes across each region. However, recombination between these relatively tractable regions has generated dramatic haplotype diversity across PON1. Indeed, using only 2 promoter and 2 coding region polymorphisms, the PHASE program inferred that 12 of 16 possible haplotypes were observed, with 8 haplotypes occurring at a frequency of Ͼ0.3% (Table 1 ). In regions with low levels of recombination, cladistic analysis would allow for grouping of haplotypes based on evolutionary relationships. Given the high frequency of recombinant haplotypes across PON1, we treated the 2 promoter area SNPs (PON1 Ϫ162/Ϫ108 , DЈϭ1) as a 2-site haplotype and analyzed the PON1 55 and PON1 192 sites separately.
Finally, we were able to estimate the amount of common genetic (MAF Ͼ0.1) variation in the PON1. Sixty SNPs were identified at greater than 10% MAF in the white CEPH population. In the present study, 4 of these sites were typed and 56 were unassayed. Of those 56, 44 
Relationship Between PON1 Genotypes and Phenotypes
As expected, the bivariate Pearson correlation between sqrtPOase and sqrt-DZOase was Ϫ0.01 (NS), although the correlation was high within PON1 192 genotypes. The correlation between sqrt-POase and sqrt-Aase was 0.22 (PϽ0.01), and the correlation between sqrt-DZOase and sqrt-Aase was 0.70 (PϽ0.01). Pack-years smoked was not significantly correlated with sqrt-DZOase (correlationϭϪ0.052, Pϭ0.42), sqrt-Aase (Ϫ0.067, Pϭ0.30), or POase (Ϫ0.019, Pϭ0.77). Current smokers had significantly lower PON1 sqrt-POase (Pϭ0.019) but not sqrt-DZOase or sqrt-Aase (Pϭ0.43) activity levels, although all activities tended to be lower in smokers. Table 2 summarizes the portion of variances in each PON1 activity measure attributable to current age, all 4 PON1 genotypes measured, statin drug use, smoking behavior, and levels of HDL, HDL2, and HDL3. Smoking behavior was evaluated both as square root of pack-years smoked and current smoking. Accurately reported, current smoking is expected to impact PON1 activity more than smoking history. 43 Cases had a larger total variance and larger portion of unexplained variance relative to controls, except for sqrtPOase, which was largely explained by PON1 192 genotype in both cases and controls (Table 2) . When jointly considered, all 4 genotypes had statistically significant effects on DZOase in controls at the PϽ0.05 level, and only the PON1 Ϫ162 polymorphism did not significantly add to the prediction of DZOase in CAAD cases. When jointly considered, the PON1 192 and PON1 Ϫ108 polymorphisms predicted variation in POase, as expected, whereas PON1 Ϫ162 and PON1 55 did not in either cases or controls. The fact that PON1 haplotypes constructed using all 4 sites did not explain a greater fraction of variance in the phenotypes than an analysis including all 4 sites separately seems to confirm that the haplotype construction did not provide additional information about unassayed functional sites in the PON1 gene.
Phenotype and Genotype Effects on Vascular Disease Prediction
As a single predictor, sqrt-DZOase (Pϭ0.016) was a significant predictor of CAAD status using matched logistic regression, with cases having lowered activity, as expected (Table  3) . Sqrt-POase (Pϭ0.355) and sqrt-Aase (0.200) were not significant for the prediction of CAAD status, although sqrt-POase became highly predictive when genotypes were jointly considered (Table 3 , model 3). All 3 PON1 activities were lower in cases than controls within the PON1 192QQ or PON1 192QR genotypes, although this was not seen in the small 
PON1 Ϫ162 and PON1 Ϫ108 polymorphisms are identified by the base change, whereas the PON1 55 and PON1 192 polymorphisms are identified by the amino acid substitutions (italics). Proportion of variance (r 2 from regression) explained for each PON1 activity measure, separately for cases and controls. Each row represents a different regression model. Variance in cases versus controls can be compared for each model, and variance explained can be compared across models. Neither columns nor rows are additive.
number of RR subjects. Separate matched analysis rejected significant marginal effects of PON1 Ϫ108 (Pϭ0.30) or PON1 Ϫ162 (Pϭ0.49) genotype, as well as PON1 Ϫ108/Ϫ162 haplotype (Pϭ0.54) in the prediction of CAAD status (Table 3) . Figure 2 demonstrates the genotype or haplotype frequencies for both cases and controls. When all PON1 Ϫ108/Ϫ162 haplotypes and PON1 55 and PON1 192 genotypes were jointly considered, none showed marginal significance for the prediction of CAAD status (Table 3, model 1). PON1 Ϫ162/Ϫ108 , PON1 55 , and PON1 192 did not become significant (all PϾ0.2) when sqrt-DZOase was considered along with the 4 genotypes in the regression model (Table 3, model  2) . However, sqrt-POase (Pϭ0.001) and PON1 192 genotype (Pϭ0.02, degrees of fractionϭ2) did become significant in the prediction of CAAD but the PON1 Ϫ162/Ϫ108 (PϾ0.2) and PON1 55 (PϾ0.2) did not when sqrt-POase was considered along with the 4 genotypes in the regression model (Table 3 , model 3).
Discussion
Evidence of historical recombination events at several positions within the PON1 gene was observed, which restricts LD to multiple small areas within and surrounding the gene. Within each small, nonrecombinant region, a limited number of local haplotypes was observed, but across the entire gene, recombination between regions has generated a large number of haplotypes. Although the recombinant structure of the PON1 locus is most obvious from the sequencing of the full gene in a group of individuals, it can also be inferred from the large number of haplotypes predicted from just 4 genotyped sites. Thus, cladistic analysis of the entire gene is not appropriate, because significant numbers of recombinant haplotypes exist but might be useful in smaller nonrecombinant regions if multiple SNPs were assayed within each region. However, whole-gene haplotypes might be useful for the prediction of disease if functional variants existed in multiple nonrecombinant regions, if the effects of these variants were not simply additive, and if appropriate groupings of haplotypes could be made to allow for reasonable power.
The finding of lowered PON1 activity in vascular disease without evident PON1 coding region genotype effects 1 has been recently confirmed in a cohort with coronary heart disease 2 and had previously been reported in myocardial infarction survivors. 44 We previously hypothesized that the lower PON1 POase and DZOase activity found in CAAD cases versus controls, not attributable to PON1 coding polymorphisms, may be due to lowered PON1 serum concentrations. 1 One speculation was that frequent PON1 promoter region polymorphisms might, at least in part, account for that result. We subsequently identified functional PON1 Ϫ162 and PON1 Ϫ108 polymorphisms 26, 27 and apparently nonfunctional PON1 Ϫ909 , PON1 -832 , and PON1 Ϫ126 polymorphisms. These polymorphisms do not account for reduced PON1 activity in CAAD versus controls, despite their large marginal effects on PON1 activity, nor do they improve disease prediction in this cohort. Leviev et al 45 reported that PON1 Ϫ909GG subjects had a marginally lower risk of myocardial infarction, particularly in subjects Ͻ50 years old. They detected no effect in subjects older than 60 years, similar to the result in our older subjects. Additionally, PON1 arylesterase activity, which is more closely related to protein level than POase or DZOase activity, performed more poorly as a predictor of CAAD status than DZOase activity. These data suggest that PON1 substrate specific activity, not simply quantity, may be important in the determination of vascular disease risk. These data continue to support the importance of PON1 activity measurement, rather than only PON1 genotype, for studies of cardiovascular risk. Indeed, we have recently shown that PON1 phenotype-genotype discordance can be used to detect novel PON1 nonsense and missense mutations. 46 What factors may account for the lower PON1 activity in the cases remains unclear. Cases have a higher variance in activity than controls. It is noteworthy that 65% of the variance in PON1 DZOase activity in controls is accounted for by the 4 genotypes measured here, but only 43% of that in the cases is explained along these lines ( Table 2 ). The LD data show substantial sequence variation in the PON1 region that is not captured by disequilibrium to typed sites. Considering the unassayed sites with MAF greater than 0.1, 48% had r 2 Ͻ0.5, with 1 of the 4 sites assayed in this cohort. The extent to which such unmeasured genetic variation contributes to the difference in PON1 activity between cases and controls remains to be determined. It will also be important to identify other genes that influence PON1 levels. Intervention and animal model studies will be of use in understanding the role of environmental factors in PON1 expression.
Addition of smoking and statin use and HDL level-related factors did not explain the difference in explained PON1 activity between cases and controls. This still leaves a large gap in our understanding of the sources of variation in cases versus controls, which requires additional investigation. PON1 activity may be altered by environmental factors, including tobacco smoking. Tobacco smoke depressed PON1 activity in ex vivo assays, 47 and current tobacco use has been reported to lower POase activity. 43 In a Costa Rican sample, PON1 192 genotype predicted myocardial infarctions only in nonsmokers, 48 suggesting the importance of jointly considering environmental factors that modify PON1 activity. Additionally, elevation of PON1 activity in statin drug users was consistent with the reported effects of Simvastatin on PON1 activity. 49 PON1 POase activity has been found to increase with pharmacological therapy with Simvastatin, possibly by reducing oxidative stress. 49 Dietary fat may also affect PON1 activity, 50 because the concentration of PON1 mRNA has been shown to increase or decrease in a strain-dependent fashion when mice are given an atherogenic diet. 51 Lipid, lipoprotein, or apolipoprotein levels have been weakly associated with PON1 activity or genotype in some 20, [52] [53] [54] but not all 12,55 studies.
In conclusion, neither the common PON1 5Ј functional regulatory variants PON1 Ϫ162 and PON1 Ϫ108 nor the environmental impact of smoking and statin use explain the relationship of PON1 activity to disease status or the large unexplained PON1 activity variance in cases. The PON1 gene is not contained in a single haplotype block, which suggests that promoter and coding region variants should be treated as independent factors and not grouped by haplotype for disease association studies. However, consideration of PON1 haplotype effects did not improve CAAD case-control prediction. This work continues to support the importance of measuring expression of genes and activity of enzymes in addition to genetic polymorphisms within and regulating a given gene.
